SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wiesner RH, Rakela J, Ishitani MB, Mulligan DC, Spivey JR, Steers JL, et al. Recent advances in liver transplantation. Mayo Clinic Proc 2003; 78: 197210.
  • 2
    Nash KL, Gimson AE. Liver transplantation. Hosp Med 2003; 64: 200204.
  • 3
    Everson GT, Trotter JF, Kugelmas M, Forman L. Immunosuppression in liver transplantation. Minerva Chir 2003; 58: 725740.
  • 4
    Vilatoba M, Contreras JL, Eckhoff DE. New immunosuppressive strategies in liver transplantation: balancing efficacy and toxicity. Current Opin Organ Transplant 2003; 8: 139145.
  • 5
    Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. J Hepatol 2003; 39: 664678.
  • 6
    Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving ≥5 years after liver transplantation. Transplantation 2000; 69: 781789.
  • 7
    Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991; 52: 185191.
  • 8
    Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001; 2: 19031917.
  • 9
    Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation. 2004; 78: 264268.
  • 10
    Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, et al Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or would complications. Liver Transpl 2003; 9: 463468.
  • 11
    Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimso AE, et al Transplantation 1999; 67: 505509.
  • 12
    Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67: 10361042.
  • 13
    Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 13011311.
  • 14
    Chapman TM, Perry CM. Everolimus. Drugs 2004; 64: 861872.
  • 15
    Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002; 24: 5358.
  • 16
    Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuuman H-J, et al. SDZ RAD, a new rapamycin derivative: pharmacologic properties in vitro and in vivo. Transplantation 1997; 64: 3642.
  • 17
    Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18: 150159.
  • 18
    Schuurman H-J, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 3235.
  • 19
    Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, Morris RE, et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294: 323332.
  • 20
    Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen H, Cambon N, et al, and the RAD 201 Study Group. International, double-blind, parallel-group study of the safety and efficacy of Certican (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral and steroids [abstract]. Transplantation 2004; 78: 15321540.
  • 21
    Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244252.
  • 22
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in de novo cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.
  • 23
    Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee JC, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Transplantation 2004; 4: 626635.
  • 24
    Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and tolerability of 40-0[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001; 71: 160163.
  • 25
    Nashan B. Review of the proliferation inhibitor everolimus. Expert Opinion Invest Drugs 2002; 12: 18455187.
  • 26
    Curtis J, Nashan B, Ponticelli C, Mourad G, Boger R, and the RAD 156 Study Group. One year results of a multicenter, open-label trial on safety and efficacy of Certican (RAD) used in combination with Simulect, corticosteroids and full or reduced dose Neoral in renal transplantation [abstract]. Am J Transplant 2001; 1(Suppl): 474.
  • 27
    Trotter JF. Sirolimus in liver transplantation [abstract]. Transplantation Proc 2003; 35(Suppl): 193S200S.
  • 28
    Rapamune prescribing information 2004. Available at: http://www.wyeth.com. Accessed: November 30, 2005.
  • 29
    Oppenheimer F, Oyen O, Viljoen H, Vitko S, Falcone A, Cremer M. 36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients [abstract]. Am J Transplant 2003; 3(Suppl): 459.
  • 30
    Formica RN, Friedman AL, Lorber, MI. Evolving role of sirolimus immunosuppression after organ transplantation. Current Opin Organ Transplant 2002; 7: 353358.
  • 31
    Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003; 4: 126137.
  • 32
    Levy G, Villamil F, Samuel D et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 16321638.
  • 33
    Magee J, Tedesco H, Pascual J, Civati, G, Filho, G, Garcia, V, et al. Efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral in de novo kidney transplant recipients: 12 months analysis [abstract]. Am J Transplant 2004; 4(Suppl): 296.
  • 34
    Whelchel J, Vitko S, Eris J, Campbell S, Burbigott B, Leone J, et al. Excellent graft function in de novo kidney transplant recipients treated with Certican, Simulect and reduced Neoral exposure: 12 month results [abstract]. Am J Transplant 2004; 4(Suppl): 297.
  • 35
    Kovarik JM, Eisen H, Dorent R, Mancini D, Vigano M, Rouilly M, et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range and influence on cyclosporine exposure. J Heart Lung Transplant 2003; 2211171125.